Sotyktu — Total Revenues
Bristol-Myers Squibb Sotyktu — Total Revenues decreased by 18.8% to $69M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 25.5%, from $55M to $69M. Over 3 years (FY 2022 to FY 2025), Sotyktu — Total Revenues shows an upward trend with a 231.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration and physician adoption of the therapy, while a decrease may signal competitive pressure or challenges in patient access and reimbursement.
Detailed definition
This metric represents the total global net sales generated from the commercialization of Sotyktu, a selective tyrosine...
Peer comparison
Comparable to revenue metrics for specialized immunology or dermatology blockbusters at peer pharmaceutical companies, often evaluated against consensus growth estimates for new product launches.
bmy_segment_sotyktu_total_revenuesHistorical Data
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $0 | $0 | $1M | $7M | $16M | $25M | $66M | $63M | $44M | $53M | $66M | $83M | $55M | $70M | $80M | $85M | $69M |
| QoQ Change | — | — | — | — | — | +600.0% | +128.6% | +56.3% | +164.0% | -4.5% | -30.2% | +20.5% | +24.5% | +25.8% | -33.7% | +27.3% | +14.3% | +6.3% | -18.8% |
| YoY Change | — | — | — | — | — | — | — | — | >999% | +800.0% | +175.0% | +112.0% | +0.0% | +31.7% | +25.0% | +32.1% | +21.2% | +2.4% | +25.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's sotyktu — total revenues?
- Bristol-Myers Squibb (BMY) reported sotyktu — total revenues of $69M in Q1 2026.
- How has Bristol-Myers Squibb's sotyktu — total revenues changed year-over-year?
- Bristol-Myers Squibb's sotyktu — total revenues increased by 25.5% year-over-year, from $55M to $69M.
- What is the long-term trend for Bristol-Myers Squibb's sotyktu — total revenues?
- Over 3 years (2022 to 2025), Bristol-Myers Squibb's sotyktu — total revenues has grown at a 231.0% compound annual growth rate (CAGR), from $8M to $290M.
- What does sotyktu — total revenues mean?
- The total revenue generated from the sales of the drug Sotyktu.